ArticleRheumatology (Oxford, England)2021
The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population-based study.
Article in Rheumatology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- A systematic review and meta-analysis of the association between the D-dimer and rheumatic diseases.Immunity, inflammation and disease · 2024Pooled it
- Risk of Multiple Sclerosis Among Users of Antitumor Necrosis Factor α in 4 Canadian Provinces: A Population-Based Study.Neurology · 2023Pooled it
- Trial
- The risk of venous thromboembolism in RA.Rheumatology (Oxford, England) · 2026Review
- Exploring the risk of venous thromboembolism in women with rheumatoid arthritis initiating menopausal hormone treatment in England.Rheumatology advances in practice · 2026Article
- The Inflammatory Link of Rheumatoid Arthritis and Thrombosis: Pathogenic Molecular Circuits and Treatment Approaches.Current issues in molecular biology · 2025Review
- Differential risk of adverse drug reactions with baricitinib across age groups: integrating real-world pharmacovigilance and genetic causal inference.Therapeutic advances in drug safety · 2025Article
- Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?Research and practice in thrombosis and haemostasis · 2025Review
- Catheter-Based Thrombectomy for Clot-In-Transit and Massive Pulmonary Embolism In A Young Patient with Rheumatoid Arthritis: Inflammation as A Hidden Catalyst for Catastrophic Thromboembolism.European journal of case reports in internal medicine · 2025Article
- Under the dual effect of inflammation and pulmonary fibrosis, CTD-ILD patients possess a greater susceptibility to VTE.Thrombosis journal · 2024Review
- Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis.Mediterranean journal of rheumatology · 2024Article
- Risk of venous thromboembolism in patients with rheumatoid arthritis: a meta-analysis of observational studies.BMC rheumatology · 2024Article
- Rheumatoid arthritis, cardiometabolic comorbidities, and related conditions: need to take action.Frontiers in medicine · 2024Review
- Clinical Characteristics and Prognosis of Acute Pulmonary Embolism with Hemoptysis in Autoimmune Disease Patients.International journal of medical sciences · 2024Article
- Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?Endocrine reviews · 2023Review
- Crucial safety issues on Janus kinase inhibitors in rheumatoid arthritis might be associated with the lack of LDL-cholesterol management: a reasoned literature analysis.Internal and emergency medicine · 2023Article
- Venous Thromboembolism After COVID-19 Infection Among People With and Without Immune-Mediated Inflammatory Diseases.JAMA network open · 2023Article
- A Narrowing Mortality Gap: Temporal Trends of Cause-Specific Mortality in a National Matched Cohort Study in US Veterans With Rheumatoid Arthritis.Arthritis care & research · 2023Article
- The association between autoantibodies and risk for venous thromboembolic events among patients with rheumatoid arthritis.Rheumatology (Oxford, England) · 2023Article
- Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases.Rheumatology and therapy · 2023Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 2 countries.
Funding
Abstract
objectivesTo estimate the overall risk of venous thromboembolism (VTE), pulmonary embolism (PE) and deep vein thrombosis (DVT) among patients newly diagnosed with RA compared with the general population without RA; and to estimate the risk trends of VTE, PE and DVT after RA diagnosis up to 5 years compared with the general population.
methodsUsing previously validated RA case definition, we conducted a matched cohort study using the population-based administrative health database from the province of British Columbia, Canada. We calculated incidence rates (IRs) and fully adjusted hazard ratios (HRs) for the risk of VTE, DVT and PE after RA index date.
resultsAmong 39 142 incident RA patients (66% female, mean age 60), 1432, 543 and 1068 developed VTE, PE and DVT, respectively. IRs for the RA cohort were 3.79, 1.43 and 2.82 per 1000 person-years vs 2.70, 1.03 and 1.94 per 1000 person-years for the non-RA cohort. After adjusting for VTE risk factors, the HRs (95% CI) were 1.28 (1.20, 1.36), 1.25 (1.13, 1.39) and 1.30 (1.21, 1.40) for VTE, PE and DVT, respectively. The fully adjusted HRs for VTE during the first five years after RA diagnosis were 1.60, 1.47, 1.40, 1.30 and 1.28, respectively. A similar trend was shown in PE.
conclusionThis population-based study demonstrates that RA patients have an increased risk of VTE, PE and DVT after diagnosis compared with the general population. This risk is independent of traditional VTE risk factors and is highest during the first year after RA diagnosis, then progressively declined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.